Agilent Technologies Presents Thought Leader Award to Influential Cancer Researcher
Biologist Scott Lowe Recognized for Contributions to Next-Generation Tools
SANTA CLARA, Calif.
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Scott Lowe has received an Agilent Thought Leader Award in recognition for his contributions to the identification of key genes – including those that promote or suppress cancer – and their characterization as therapeutic targets using novel genetic screens and animal models.
Dr. Lowe chairs the Cancer Biology & Genetics Program at the Sloan Kettering Institute as well as the Geoffrey Beene Cancer Research Center at the Memorial Sloan Kettering Cancer Center and is widely recognized for his work in cancer biology.
The award will support Dr. Lowe’s work on the development and implementation of next generation CRISPR-based genetic screens to systematically identify and characterize novel targets for cancer therapeutics. Notably, Agilent will support the work in Dr. Lowe’s laboratory by providing unique capabilities for the gen

